Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells

Abstract

The survival of patients affected by cutaneous melanoma has improved dramatically in the last 10 years, because of earlier diagnosis. Despite this, the therapeutic results obtained in metastatic melanoma (MM) are very disappointing due to its poor responsiveness to cytotoxic agents. In this type of solid tumor, tumor chemosensitivity assays have been suggested to be an important tool to predict clinical responsiveness to therapy. Metastatic melanoma cells (MMCs) were obtained from subcutaneous melanoma metastases of five patients and cultured for several consecutive passages. An immunofluorescence and an electron microscopic study were performed in order to establish the ultrastructural and physiopathological features of MMCs. A sulphorodamine-B test was used to measure in vitro sensitivity of MMCs to temozolomide, cisplatin, vindesine, taxol and interpheron alpha-2a. Following a 72 h exposure, maximum activity was obtained with vindesine (median inhibitory concentration, IC 50 , 0.23 nM) and taxol (median IC 50 0.31 nM). Cisplatin median IC 50 values were higher (4.6 mM) than taxol and vindesine, but still in the range of clinically achievable plasma concentrations. Temozolomide inhibited cell proliferation only at very high concentrations (median IC 50 228 mM). No significant cell growth inhibitory effects (#25%) were observed with interferon alpha-2a concentrations up to 8000 IU/ml. MMCs expressed progression markers typical of cutaneous metastatic melanoma and showed poor sensitivity in vitro to most anticancer drugs tested, including temozolomide. q

P-Hydroxycinnamaldehyde Induces B16-F1 Melanoma Cell Differentiation via the RhoA-MAPK Signaling Pathway

“…Melanoma is the deadliest form of skin cancer, and although it accounts for only 4% of skin cancer cases, it is responsible for 80% of skin cancer-related deaths [1]. The median survival time of patients with metastatic melanoma is 8-9 months, and the 3-year overall survival rate is less than 15% [2].…”

Stem cell factor affects tumour progression markers in metastatic melanoma cells

“…In a previous study we demonstrated that some immunophenotypical markers, including c-kit, of cutaneous metastatic melanoma cells (MMC) could affect the chemosensitivity of these cells; therefore the behaviour of MMC appeared predictable according to their phenotype [13].…”

Avaliação dos efeitos da subfração Acetato de etila III de Vemonia scorpioides em modelo de melanoma murino in vivo e in vitro

“…Algumas lactonas sesquiterpênicas contém uma estrutura funcional em comum (α-metileno-γ lactona) que é a responsável por interferir na via de sinalização do NF-kappaB e nas proteínas MAPK (Proteínas Kinases Mitogênicas Ativadas) indutoras de mitose . Lactonas sesquiterpênicas modificadas em laboratório têm sido testadas in vitro contra uma série de células tumorais, sendo que algumas apresentam atividade antitumoral e outras não (QUINTERO et al, 1999).…”